HSBC Holdings’s Immunocore IMCR Stock Holding History

HSBC Holdings’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-65,784	Closed	-$4.28M	–	3049
2024 Q1	$4.28M	Buy	65,784 +1,365	+2%	+$93.7K	﹤0.01%	1164
2023 Q4	$4.45M	Buy	+64,419	New	+$3.35M	﹤0.01%	1195

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HSBC Holdings's IMCR Position: Q2 2024 in Review

HSBC Holdings sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 65,784 shares — an estimated $4.28M sold.

HSBC Holdings first reported a position in IMCR in Q4 2023 and held it in 2 quarters. The position peaked at $4.45M in Q4 2023. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

HSBC Holdings reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
HSBC Holdings sold 65,784 Immunocore shares in Q2 2024, an estimated $4.28M.
HSBC Holdings first reported a position in Immunocore in Q4 2023 and held it in 2 quarters.
HSBC Holdings's Immunocore position peaked at $4.45M in Q4 2023.
138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on HSBC Holdings's 13F filing for Q2 2024, filed 12 Aug 2024.